Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC. Testa MA, et al. Among authors: blonde l. J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31. J Clin Endocrinol Metab. 2012. PMID: 22851487 Clinical Trial.
Defining and measuring quality of diabetes care.
Blonde L, Dey J, Testa MA, Guthrie RD. Blonde L, et al. Prim Care. 1999 Dec;26(4):841-55. doi: 10.1016/s0095-4543(05)70134-2. Prim Care. 1999. PMID: 10523463 Review.
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Among authors: blonde l. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L. Sullivan SD, et al. Among authors: blonde l. Diabetes Obes Metab. 2018 Sep;20(9):2148-2158. doi: 10.1111/dom.13345. Epub 2018 Jun 25. Diabetes Obes Metab. 2018. PMID: 29938887 Free PMC article.
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
Del Prato S, Frias JP, Blonde L, Aroda VR, Shehadeh N, Saremi A, Dex T, Niemoeller E, Souhami E, Liu M, Rosenstock J. Del Prato S, et al. Among authors: blonde l. Diabetes Obes Metab. 2020 Sep;22(9):1567-1576. doi: 10.1111/dom.14068. Epub 2020 May 28. Diabetes Obes Metab. 2020. PMID: 32323437 Free PMC article. Clinical Trial.
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Meneghini L, Blonde L, Gill J, Dauchy A, Bacevicius A, Strong J, Bailey TS. Meneghini L, et al. Among authors: blonde l. Diabetes Obes Metab. 2020 Nov;22(11):1995-2003. doi: 10.1111/dom.14116. Epub 2020 Jul 27. Diabetes Obes Metab. 2020. PMID: 32538550 Free PMC article. Clinical Trial.
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat MM. Home PD, et al. Among authors: blonde l. Diabetes Obes Metab. 2020 Nov;22(11):2170-2178. doi: 10.1111/dom.14136. Epub 2020 Jul 26. Diabetes Obes Metab. 2020. PMID: 32627297
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Rosenstock J, Blonde L, Aroda VR, Frias J, Souhami E, Ji C, Niemoeller E, Del Prato S. Rosenstock J, et al. Among authors: blonde l. Diabetes Obes Metab. 2021 Jun;23(6):1331-1341. doi: 10.1111/dom.14345. Epub 2021 May 4. Diabetes Obes Metab. 2021. PMID: 33565209 Free PMC article.
201 results